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The aim of this study was to clarify the association between 
the inosine triphosphate pyrophosphatase (ITPA) gene vari-
ants and PEG-IFNĮ/RBV combination treatment induced 
anemia in chronic hepatitis C (CHC) Ukrainian patients. 
The data were collected from 80 CHC patients with HCV 
genotype 1 infection. All study participants received standard 
doses of PEG-IFNĮ and RBV. According to the Hb level 
changes patients were distributed into: case group – 42 
patients with combination treatment induced anemia, and 
control group – 38 patients with no signs of anemia. Ge-
notyping for ITPA gene rs1127354 and rs7270101 variants 
was performed using PCR followed by RFLP assay. Fisher’s 
exact test was used to estimate the difference in genotype and 
allelic distribution. Distribution of rs7270101 genotypes was 
not significantly different between groups of CHC patients 
with RBV-induced anemia and without it. The frequency 
of rs1127354 A allele carriers was significantly higher (P < 
< 0,05) in group of CHC patients without anemia (23,7 %) 
comparing to the group of patients with anemia (7,3 %). The 
respective allele frequency in control group (13,2 %) was 
almost 3-fold higher (P < 0,05) comparing to the case group 
(4,9 %). Significant association of ITPA gene rs1127354 
with protection against RBV-induced hemolytic anemia was 
found in Ukrainian patients with CHC infection. Rs1127354 
variant may assist as a pharmacogenetic marker in HCV 
antiviral therapy correction for side effect avoidance.
Key words: chronic hepatitis C, ITPA gene, side effects, 
hemolytic anemia, pharmacogenetics.
Introduction. An estimated number of 150 million 
people is currently affected by hepatitis C virus 
(HCV) infection, which corresponds to 2.35 % of 
the world population [1]. In 70–80 % cases a pri-
mary HCV infection develops into chronic infec-
tion with its complications of liver cirrhosis and/
or hepatocellular carcinoma [2]. Current approach 
to chronic hepatitis C (CHC) antiviral treatment 
includes pegylated interferon alfa (PEG-IFN) and 
ribavirin (RBV) combination therapy [3]. However, 
despite its advances in the treatment of CHC, com-
bination therapy is also associated with various toxic 
affects like psychiatric illness, constitutional side 
effects, and cytopenias [4]. The most common side 
effect of RBV treatment is hemolytic anemia which 
is also the major cause for RBV dose reduction [5]. 
Studies report that those patients receiving less than 
60 % of the initially selected RBV dose have a lower 
response rate and a higher relapse rate comparing 
to patients receiving a higher dose [6].
In recent years, genome-wide association studies 
(GWASs) have demonstrated a strong association 
between single nucleotide polymorphisms (SNP) of 
the inosine triphosphate pyrophosphatase (ITPA) 
gene and RBV-induced anemia in a cohort of pa-
tients infected with HCV genotype 1 [7]. The identi-
fied SNP was found on chromosome 20: rs1127354 
(missense variant in exon 2, 94C > A mutation) 
and rs7270101 (splicing-altering SNP in intron 2, 
IVS2 + 21A > C mutation) [8]. Both rs1127354 
and  rs7270101 functional variants are known to 
cause missplicing of exons 2 and 3 causing the syn-
thesis of protein with reduced enzyme activity [9] 
and consequently may be associated with protective 
phenotype against RBV-induced anemia.
Although CÍÑ is widespread in Ukraine, it has 
not been spotlighted from the standpoint of host ge-
netic studies. The motivation to conduct this study 
was to clarify for the first time in CHC Ukrainian 
patients the association between the variants of the 
ITPA gene and PEG-IFNĮ and RBV combination 
treatment induced anemia.
Methods. The data of this study were collected 
from 80 Ukrainian CHC patients (43 females, 37 
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males). All were positive for HCV RNA for more 
than 6 months and mono-infected with chronic 
hepatitis C with no evidence of HIV or hepatitis 
B infection. All participants were treatment-naive 
patients with no evidence of the presence of any 
associated liver diseases other than chronic viral 
hepatitis C. The pretreatment HCV RNA level was 
detected by quantitative real time polymerase chain 
reaction (PCR) technique with a lower limit of de-
tection of 300 IU/mL. The high viral load (RNA 
HCV ޓ 600 000 IU/ml) was observed in 46,25 % 
of patients. Qualitative PCR by TaqMan assay was 
used for detection of viral load at weeks 4, 12, 
24 and 48. HCV genotype determination was by 
sequence determination in the 5ƍ-nonstructual re-
gion of the HCV genome followed by phylogenetic 
analysis. In all the patients enrolled in this study the 
HCV genotype 1 infection was detected.
All patients underwent a pretreatment liver biopsy 
in order to evaluate liver disease activity and fibro-
sis stage which were scored by the Metavir scoring 
system. Patients with fibrosis stage of F4 and higher 
were excluded from the study as they are more prone 
to cytopenic syndrome regardless of treatment. All 
study participants received standard doses of the 
combination treatment of PEG-IFNĮ and RBV. In 
the first week of treatment, all patients were given 
the fully recommended dosages of RBV. During the 
course of treatment Hb level measurements were 
performed at least 6–12 times (every 2–4 weeks) 
for every patient. The steady decrease of Hb level 
below 130 g/l for men and 120 g/l for women was 
considered as anemia. According to the Hb level 
changes all the patients were distributed into two 
groups: case group – 42 patients with combination 
treatment induced anemia, and control group – 38 
patients with no signs of anemia. Additionally, a 
group of 100 unrelated healthy donors from gen-
eral population of Ukraine (50 females, 50 males) 
was genotyped for studied polymorphisms. Informed 
consent was obtained from all participants prior to 
the collection and storage of blood samples for ITPA 
polymorphism testing. The study has been approved 
by The Bioethical Committee of Institute of Mo-
lecular Biology and Genetics of NAS of Ukraine.
The protocol specified a treatment duration of 48 
weeks. The majority of patients (55,0 %) received 
PEG-IFNĮ2a (Pegasys) at a dose of 180 g per week 
and 45,0 % received PEG-IFNĮ2b (Pegintron) as 
Table 1. Genotype and allele distribution of ITPA gene 
rs1127354 and rs7270101 variants in studied groups
Genotype/
Allele
Anemia 
group
Control 
group
Population 
group
n % n % n %
rs1127354
Genotype
C/C
C/A
A/A
Allele
C
T
38
2
1
92,7
4,9
2,4
95,1
4,9
29
8
1
76,3
21,1
2,6
86,8
13,2
81
17
2
81,0
17,0
2,0
89,5
10,5
rs7270101
Genotype 
A/A
A/C
C/C
Allele 
A
C
34
8
0
81,0
19,1
0,0
90,5
9,5
31
7
0
81,6
18,4
0,0
90,8
9,2
85
14
1
85,0
14,0
1,0
92,0
8,0
Table 2. Comparative analysis of rs1127354 and rs7270101 minor allele population frequencies
Note. p – Fisher’s exact test results (2-tailed p-value). MIF – minor allele frequency. * Calculated between 
respective population and Ukrainian population.
Population rs1127354 MIF p* rs7270101 MIF p*
European
Eastern Asian
African
Ad Mixed American
Ukrainian
0,078
0,131
0,047
0,052
0,105
0,277
0,404
0,009
0,03
0,12
0,0
0,087
0,075
0,08
0,134
0,8821
0,9371
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a subcutaneous injection at a dose of 1.5 g/kg per 
week. All patients received a 15 mg/kg daily oral 
dose of RBV (Copegus or Rebetol). However, the 
study was designed with a futility-stopping rule that 
would halt the trial if there was < 2 log10 HCV RNA 
decline at week 12 or persistent viremia at week 24. 
DNA from 80 CHC patients and 100 healthy 
donors from general population of Ukraine was ex-
tracted by standard method using proteinase K with 
the following chlorophorm extraction. ITPA gene 
DNA sequence was amplified by routine PCR using 
mismatched primers to create an XmnI restriction 
sites as described elsewhere [10].
Statistical analysis has been performed using 
GenePop and OpenEpi statistical packages [11, 12]. 
Fisher’s exact test was used to estimate the differ-
ence in genotype and allelic distribution. A P-value 
of less than 0.05 was regarded as significant.
Results. The genotype and allele distributions 
for rs1127354 and rs7270101 variants are present-
ed in the table 1. Genotype distribution for both 
studied polymorphisms in three studied groups was 
according to Hardy-Weinberg equilibrium. Com-
parative analysis of previously reported rs1127354 
and rs7270101 variant minor allele population fre-
quencies [13] and results obtained in this study is 
shown in table 2. 
There were no differences found in rs7270101 
variant allele distribution reported for super popula-
tions, which are part of 1000 Genomes project [13] 
and the ones revealed in this study. On the other 
hand, rs1127354 variant allele distribution in Ukrain-
ian population was significantly different compared 
to African and Ad Mixed American populations.
Genotype and allele distributions of rs1127354 
and rs7270101 did not differ between popula-
tion group and groups of patients with or with-
out anemia. Distribution of rs7270101 genotypes 
was not significantly different between groups of 
CHC patients with RBV-induced anemia and with-
out it. The significant difference was observed in 
rs1127354 allele and genotype distributions between 
studied groups of patients. The rs1127354 A al-
lele carriers frequency was significantly higher (p =
= 0,04) in group of CHC patients without anemia 
(23,7 %) comparing to the group of patients with 
anemia (7,3 %). The respective allele frequency in 
group of CHC patients without anemia (13,2 %) 
was more than twofold higher comparing to the 
case group (4,9 %).
Discussion. To our knowledge, this is the first 
study to assess the impact of the rs1127354 and 
rs7270101 ITPA genotypes on the RBV-induced ane-
mia development in Ukrainian patients with chronic 
hepatitis C infection, regardless of the outcome of 
treatment. Several previous studies have also demon-
strated the protective benefit of the rs1127354 allele 
A against RBV-induced anemia during the first 12 
weeks of treatment [14, 15].The protective impact of 
ITPA deficiency is supposed to be as follows. RBV-
induced anemia mechanism includes an oxidative 
damage to erythrocyte membranes and extravascu-
lar erythrophagocytosis provoked by accumulation 
of the RBV metabolite – triphosphorylated RBV 
[16]. ITPA deficiency causes a strong accumulation 
of inosine triphosphate (ITP) which competes with 
triphosphorylated RBV in erythrocytes and protects 
cells from the hemolytic effects [17]. Anemia is re-
ported to be a major cause of RBV dose reduction, 
which in 10–14 % of HCV-infected patients extends 
to early withdrawal from treatment in the first 12 
weeks [5]. Taking into the account our results as 
well as results obtained in other studies, RBV dose 
reduction in the early weeks of treatment is evidently 
necessary for patients with rs1127354 CC.
In conclusion, the significant association of ITPA 
gene rs1127354 with protection against RBV-in-
duced hemolytic anemia has been found in Ukrain-
ian patients with chronic hepatitis C infection. ITPA 
genotyping, may assist in HCV antiviral therapy cor-
rection in patients, particularly ones at high risk for 
hemolytic anemia or anemia-related morbidity.
This work was supported by the National Academy 
of Sciences of Ukraine [grant ¹ 0112U002108]; the 
State of Ukraine [grant ¹ 0113U006253] and the 
President of Ukraine grant for talented youth.
ÀËËÅËÜÍÛÉ ÂÀÐÈÀÍÒ ÃÅÍÀ ITPA 
ÌÎÆÅÒ ÇÀÙÈÙÀÒÜ ÏÀÖÈÅÍÒÎÂ 
Ñ ÕÐÎÍÈ×ÅÑÊÈÌ ÃÅÏÀÒÈÒÎÌ Ñ 
ÈÇ ÓÊÐÀÈÍÛ ÏÐÎÒÈÂ ÀÍÅÌÈÈ, 
ÈÍÄÓÖÈÐÎÂÀÍÍÎÉ ÊÎÌÁÈÍÈÐÎÂÀÍÍÎÉ 
ÒÅÐÀÏÈÅÉ ÏÅÃÈËÈÐÎÂÀÍÍÛÌ 
ÈÍÒÅÐÔÅÐÎÍÎÌ È ÐÈÁÀÂÈÐÈÍÎÌ
À.Ì. Êó÷åðåíêî, Â.Í. Ïàìïóõà, È.À. Áîáðîâà, 
Ë.Â. Ìîðîç, Ë.À. Ëèâøèö 
Öåëüþ íàñòîÿùåãî èññëåäîâàíèÿ áûëî èçó÷èòü àñ-
ñîöèàöèþ àëëåëüíûõ âàðèàíòîâ ãåíà èíîçèí òðè-
ôîñôàò ïèðîôîñôàòàçû (ITPA) ñ àíåìèåé, èíäóöè-
ðîâàííîé êîìáèíèðîâàííîé òåðàïèåé ïåãèëèðîâàí-
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íûì èíòåðôåðîíîì (PEG-IFNĮ) è ðèáàâèðèíîì (RBV)
ó ïàöèåíòîâ èç Óêðàèíû ñ õðîíè÷åñêèì ãåïàòèòîì Ñ
(ÕÃÑ). Äàííûå ñîáðàíû ó 80 ïàöèåíòîâ ñ ÕÃÑ,
êîòîðûå èìåëè ïåðâûé ãåíîòèï âèðóñà. Âñå ó÷àñò-
íèêè èññëåäîâàíèÿ ïîëó÷àëè ñòàíäàðòíûå äîçû 
PEG – IFNĮ è RBV. Â ñîîòâåòñòâèè ñ èçìåíåíèÿìè 
óðîâíÿ ãåìîãëîáèíà ïàöèåíòû áûëè ðàçäåëåíû íà 
èññëåäóåìóþ ãðóïïó (42 ïàöèåíòà ñ àíåìèåé) è êîíò-
ðîëüíóþ (38 ïàöèåíòîâ áåç ïðèçíàêîâ àíåìèè). Ãå-
íîòèïèðîâàíèå ïîëèìîðôíûõ âàðèàíòîâ rs1127354
è rs7270101 ãåíà ITPA ïðîâîäèëè ñ ïîìîùüþ ÏÖÐ ñ 
ïîñëåäóþùèì ÏÄÐÔ àíàëèçîì. Ðàñïðåäåëåíèå ãåíî-
òèïîâ ïî ïîëèìîðôíîìó âàðèàíòó rs7270101 äîñòî-
âåðíî íå îòëè÷àëîñü â ãðóïïå ÕÃÑ ïàöèåíòîâ ñ
RBV-èíäóöèðîâàííîé àíåìèåé è áåç íåå. ×àñòîòà 
íîñèòåëåé àëëåëÿ rs1127354 A áûëà âûøå â ãðóï-
ïå ïàöèåíòîâ c ÕÃÑ áåç àíåìèè (23,7 %) ïî ñðàâíå-
íèþ ñ ãðóïïîé ïàöèåíòîâ ñ àíåìèåé. ×àñòîòà ñîîò-
âåòñòâóþùåãî àëëåëÿ â êîíòðîëüíîé ãðóïïå (13,2 %)
áûëà âûøå, ÷åì â ãðóïïå ïàöèåíòîâ ñ àíåìèåé 
(4,9 %) ïî÷òè âòðîå. Íàéäåíà äîñòîâåðíàÿ àññîöèà-
öèÿ ïîëèìîðôíîãî âàðèàíòà rs1127354 ãåíà ITPA 
ñ ïðîòåêöèåé ïðîòèâ ðèáàâèðèí-èíäóöèðîâàííîé 
ãåìîëèòè÷åñêîé àíåìèè ó ïàöèåíòîâ èç Óêðàèíû ñ 
ÕÃÑ. Ïîëèìîðôíûé âàðèàíò rs1127354 ìîæåò ñëó-
æèòü ôàðìàêîãåíåòè÷åñêèì ìàðêåðîì äëÿ êîððåê-
öèè ïðîòèâîâèðóñíîé òåðàïèè ãåïàòèòà Ñ âî èçáå-
æàíèå ïîáî÷íûõ ýôôåêòîâ.
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